medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (1)

Myelodysplastic syndrome and immune system

Duarte PY, Triana MY, Marsán SV

Language: Spanish
References: 43
Page: 1-18
PDF size: 280.16 Kb.


ABSTRACT

Introduction: Myelodysplastic syndromes (MDS) constitute a heterogeneous group of acquired clonal hematological disorders that affect the stem cell. These are characterized morphologically and clinically by: ineffective hematopoiesis, progressive peripheral cytopenia, dysplasia in one or more cell lineages, in most of cases and evolutionary tendency to acute leukemia. Recent advances in understanding the genetic and molecular mechanisms of MDS have revealed the association between immunological alterations and recurrent mutations. Cells of the innate and adaptive immune response, as well as various soluble mediators released by them, can establish a protective antitumor response or, on the contrary, induce events of chronic inflammation that favor the promotion and progression of this disease.
Objective: To summarize the current knowledge of the immune system-MDS relationship, emphasizing the immune cells of the bone marrow microenvironment and their importance in the clinic of the disease.
Methods: A bibliographic-documentary research was carried out on the subject. The Scielo and Pubmed databases were consulted.
Conclusions: Understanding the dual role of the immune system in MDS constitutes a challenge and rigorous clinical studies are necessary to establish the value of manipulating the immune system as a possible form of treatment of this disease.


REFERENCES

  1. Rodríguez JH, Del Luján Acosta I. Actualización en síndromes mielodisplasicos (SMD). RevMed Rosario. 2011;77: 24-41.

  2. Aires A, dos Anjos Teixeira M, Lau C, Moreira C, Spínola A. A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk: the "MD Smyelodysplastic syndromes thermometer". BMC Hematology.2018;18:6.

  3. Kornblihtt L. Síndromes Mielodisplásicos: aspectos epidemiológicos. Hematología. 2020; 14(3):79-85.

  4. Rozo-Agudelo PA, Jaramillo-Arbelaez PE. Características citogenéticas de adultos con síndromes mielodisplásicos según criterios de clasificación de la OMS. Hematol Méx.2020; 21(2):103-14.

  5. Alfonso G, Arbelbide J, Basquiera AL, Cismondi V, Crisp R, De Dios Soler M, et al. Síndromes mielodisplásicos y síndromes de superposición mielodisplasia/ neoplasia mieloproliferativa. En: Sociedad Argentina de Hematología. Guías de diagnóstico y tratamiento [Internet]. Buenos Aires: Sociedad Argentina de Hematología;2019 [acceso 06/05/2020]. Disponible en: Disponible en: http://www.sah.org.ar/docs/2019/Sindromes_Mielodisplasicos_y_Sindromes_de_Superposicion_Mielodisplasia_Neoplasia_Mieloproliferativa.pdf

  6. Valent P, Orazi A, Steensma DP, Ebert BL, Haase D. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget.2017; 8(43): 73483-500.

  7. Sarhan D, Wang J, Arvindam US, Hallstrom C, Verneris MR. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. -JCI Insight. 2020;5(5):130-55.

  8. Filippini S, Flores G, Iastrebner M. El rol del sistema inmune en la patogenia de los síndromes mielodisplásicos y sus implicancias terapéuticas. Hematología. 2017;21(2): 188-96.

  9. Li AJ, Calvi LM. The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression. Exp Hematol. 2018; 55:3-18.

  10. Filippini SE. Rol del sistema inmune y del microambiente en SMD. Hematología. 2017;21(Extraordinario), XXIII Congreso Argentino de Hematología: 71-6.

  11. Poon Z. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. Leukemia. 2019; 33(6):1487-500.

  12. Rivera-Cruz CM, Shearer JJ, Figueiredo Neto M, Figueiredo ML. The immunomodulatory effects of mesenchymalstem cell polarization within the tumor microenvironment niche. Stem Cells Int. 2017; 40:15-39.

  13. Corradi G. Mesenchymal stromal cells from myelodysplastic and acutemyeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Res Ther. 2018; 9(1):271.

  14. Gastaldi Cominal J, da Costa Cacemiro M, Pinto-Simões B, Kolb HJ, Ribeiro Malmegrim KC, Attié de Castro F. Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies. Stem Cells Int.2019; 2019:6854080. DOI: https://doi.org/10.1155/2019/6854080.

  15. Pleyer L, Valent P, Greil R. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int. J. Mol. Sci. 2016;17:1009.

  16. Han Y, Wang H and Shao Z. Monocyte-Derived Macrophages Are Impaired in Myelodysplastic Syndrome. J Immunol Res. 2016;2016:5479013. DOI: https://10.1155/2016/5479013

  17. Rathnayake AJIS, Goonasekera HWW, Dissanayake VHW. Phenotypic and Cytogenetic Characterization of Mesenchymal Stromal Cells in De Novo Myelodysplastic Syndromes. Anal Cell Pathol (Amst). 2016; 11:65.

  18. De Hollanda A. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res. 2011; 63:1188-94.

  19. Boddu PC, Zeidan AM. Myeloid disorders after autoimmune disease. Best Pract Res Clin Haematol. 2019 Mar;32(1):74-88. DOI: https://10.1016/j.beha.2019.02.002

  20. Mekinian A, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes andchronic myelomonocytic leukaemia: A French multicenter retrospective study. Rheumatology (Oxford). 2016;55:291-300.

  21. Kristinsson S, et al. Chronicimmune stimulation mightact as a trigger for the development of acutemyeloidleukemiaor myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-903.

  22. Komrokji R, et al. Autoimmune diseases and myelodysplastic syndromes. Am. J. Hematol.2016; 91:280-3.

  23. Banerjeea T, Calvib LM, Beckerc MW, Liesveldc JL. Flaming and fanning: The Spectrum of inflammatoryinfluences in myelodysplastic syndromes. Blood Rev. 2019; 36:57-69.

  24. Glenthøj A, DueØrskov A, Hansen JW, Hadrup SR, O'Connell C,Grønbæk K. ImmuneMechanisms in Myelodysplastic Syndrome. IntJ Mol Sci. 2016; 17: 944.

  25. Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018; 97(11):2015-23.

  26. Lambert C, Wu Y, Aanei C. Bone Marrow Immunity and Myelodysplasia. Front Oncol. 2016 Jul;6:172. DOI: https://10.3389/fonc.2016.00172

  27. Wolach O, Stone R. Autoimmunity and Inflammation in Myelodysplastic Syndromes. Acta Haematol. 2016; 136:108-17.

  28. Martín-Antonio B, Suñe G, Perez-Amill L, Castella M, Urbano-Ispizua A. Natural Killer Cells: Angels and Devils for Immunotherapy.Int J Mol Sci. 2017; 18:1868.

  29. Ruggeri L, Parisi S, Urbani E, Curti A. Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy. Front Immunol. 2015 Oct;6:479. DOI: https://10.3389/fimmu.2015.00479

  30. Song M, Wang H and Ye Q. Increased circulating vascular endothelial growth factor in acute myeloid Leukemia patients: a systematic review and metaanalysis. Systematic Rev. 2020;9:103.

  31. Geyh S, Rodríguez-Paredes M, Jäger P,Koch A, Bormann F. Transforming growth factor ß1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acutemyeloid leukemia. Haematologica. 2018; 103(9):1462-71.

  32. Shen HH, Yang YX, Meng X, Luo XY, Li XM, Shuai ZW, et al. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmune Rev. 2018; 17:694-702.

  33. Giudice V, Wu Z, Kajigaya S, Fernández MDP, Rios O, Cheung F, et al. Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes. Cytokine. 2018; 113:462-5.

  34. Chiqueto L, Schuettpelz LG. Contribution of aberrant toll like receptor signaling to the pathogenesis of myelodysplastic syndromes. Front Immunol. 2020; 11:1236.

  35. Cannova J. Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases. Front Med. 2015; 9(3):288-303.

  36. Kam AYF, Piryani SO, McCall CM, Park ES, Doan PL. Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome. Clin Cancer Res. 2019; 25:4155-67.

  37. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013; 27(9):1832-40.

  38. Yang L, Qian Y; Eksioglu E; Epling-Burnette PK; Wei S. The inflammatory microenvironment in MDS. Cell Mol LifeSci. 2015; 72:1956-66.

  39. Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, et al. Cancer immuno surveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell. 2016; 164(3):365-77.

  40. Iannello A, Thompson TW, Ardolino M, Marcus A, Raulet DH. Immuno surveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol. 2016; 38:52-8.

  41. Gañán-Gómez I. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015; 29:1458-69.

  42. Zambetti NA, Ping Z, Chen S. Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia. Cell Stem Cell.2016;16:59-66.

  43. Pavlaki K, Pontikoglou CG, Demetriadou A. Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev. 2014; 23:1568-81.




2020     |     www.medigraphic.com